抑制血管生成治疗子宫内膜异位症的临床研究  

A Clinical study on anti-angiogenesis therapy for endometriosis

作　　者：徐宇虹[1] 

机构地区：[1]开平市中心医院妇产科,529300

出　　处：《国际医药卫生导报》2012年第11期1587-1588,共2页International Medicine and Health Guidance News

摘　　要：目的探讨抑制血管生成治疗方式对子宫内膜异位的临床疗效。方法选取2007年3月至2011年6月来我院就诊治疗的子宫内膜异位症60例，随机分为2组，治疗组30例，采用米非司酮联合腹腔镜手术治疗；对照组30例，单独采用腹腔镜手术。比较分析两组患者的治疗疗效和血管密度（MVD）。结果治疗组患者治疗有效患者25例，总有效率为83．3％，在位内膜微血管密度（14±3）条，异位内膜微血管密度（13±3）条；对照组患者治疗有效17例，总有效率为56．7％，在位内膜微血管密度（23±4）条，异位内膜微血管密度（27±2）条，P〈0．05。结论米非司酮是一种很好的血管抑制药物，它可以有效降低病灶的微血管密度并提高治疗效果。Objective To investigate the clinical efficacy of anti-angiogenesis therapy for endometriosis. Meth- ods 60 patients with endometriosis who visited our hospital from March 2007 to June 20111 were randomly assigned to receive mifepristone combined with laparoscopic surgery （ 30 patients, study group ）, or laparoscopic surgery alone （ 30 patients, control group ）. The efficacy and microvessel density （ MVD ） were compared and analyzed. Results In the study group, the total effectiveness rate was 83.3% （ 25 patients ）, with eutopic endometrial microvascular density of 14± 3 and ectopic endometrial microvascular density of 13 ± 3; whereas inn the control group, the total effectiveness rate was 56.7% （ 17 patients ）, with eutopic endometrial microvascular density of 23 ± 4 and ectopic endometrial microvascular density of 27±2 （ P 〈 0.05 ）. Conclusions Mifepristone is a great antiangiogenic drug. It can effectively reduce the density of blood vessels in lesions and improve the therapeutic effect.

关 键 词：子宫内膜异位症 血管生成 临床研究 

分 类 号：R711.71[医药卫生—妇产科学]